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THE SURGEON GENERAL’S 
ANSWER TO THE OPIOID CRISIS
by Jamie M. Rebman, Department of Chemistry  
The Epidemic
Every day 115 Americans overdose 
1 every 12.5 minutes
42,249 US drug fatalities -- 66% of 
the total
~1,000 more than breast cancer 
deaths (also more than car 
accidents)
More than half of deaths occur at 
home, before first responders 
arrive or victims can get to facility 
Who is being affected? 
77% die outside 
medical facility.
Demographics:
Rx painkillers → addiction (→ $$ → Heroin)
Demographics:
http://nprillinois.org/post/illinois-issues-saving-lives-fight-against-heroin#stream/0











Opium from Poppy plant







THE SURGEON GENERAL’S PLAN
The Advisory 
April 5, 2018
Last Surgeon General issued Advisory -- February 2005.
Surgeon General’s Vison
Needs to be as commonplace as 
CPR 
Foresees the day when drug is as 
widespread as fire extinguishers





Recognizing an Opioid Overdose
▪Symptoms:
▪ Pinpoint Pupils
▪ Blue Skin, Nail Beds
▪ Drowsiness
▪ Reduced Heart Rate
▪ Confusion, Lessened Alertness
▪ Slowed, Depressed, Shallow Breathing
→  Unconsciousness
→   Respiratory Failure
Elevated Risk 
•  Misusing prescription opioids (like oxycodone) or having an opioid use disorder
• Recent discharge from hospital or recovering from illness, recent released from incarceration or 
rehabilitation (lower tolerance)
• Combining medications
•  Using illicit drugs with unknown purity, such as heroin
•  Injecting prescription or illicit opioids




Alkaloid (Organic Nitrogenous Base) 
 Thebaine derivate
Melting Point: 178-205 °C
http://www.hmdb.ca/spectra/
LC-MS/MS
GC-MS Physical          Properties
Soluble in Water, Chloroform
Heat decomposition emits toxic fumes
Aromatic heteropolycyclic
Lipophilic 




Oxymorphone demethylated   →   4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one 
+ Ethanol + Allyl Bromide + NaHCO3                                            Naloxone 
n-allylated
+ Ethanolic hydrochloride → Naloxone hydrochloride 
Naloxone:







1st FDA approval - 1971
Other names and Info
• Not to be confused with Naltrexone 
• Used for opioid dependence. 
• Chemical structures are very similar
























• Opiate Antagonist – prevents or quickly 




• No opioid, no effects 
• Binds strongest to mu receptor






• Moderate to Severe Pain
• Septic Shock 
• Off Label Uses*: 
• cardiogenic shock
• high-altitude pulmonary edema
• acute respiratory failure
• senile dementia
• ischemic neurologic deficits
*the safety and efficacy of naloxone in these conditions have 
not been established and further study is needed
Image: http://healthland.time.com/2012/02/17/lifesaving-overdose-antidote-should-be-made-more-widely-available/
Side Effects and 
Interactions
Hepatically metabolized, primarily via 
glucuronidation  →  naloxone-3-glucuronide
Elimination via urine (25%- 40% is 
excreted as metabolites within 6 
hours)
The serum concentration or metabolism of 
Naloxone can be increased or decreased 
with certain medications (interacts with 
107)
May immediately experience opioid withdrawal 
symptom: 
Nausea, vomiting, sweating, aches, tremors, rapid 
pulse, and diarrhea
Not life-threatening like alcohol withdrawals
Short duration of action




Use in ultra-rapid detoxification - controversial
Cytochromes P450  2C8 and 3A4
Forms of Naloxone 
Available Forms 
http://induced.info/?s=NARCAN+Nasal+Spray+4mg












What are the 
differences?
Combinations and Novel Forms
Buprenorphine 8 MG / Naloxone 2 MG Sublingual Tablet [Suboxone] – 
Prevents misuse and abuse of buprenorphine 
Naloxone eye drop 
–Identification of 
opium dependency 
Security -- personal 
morphine vaporization 
device




• Available in most States
• Becoming more easily 
obtainable
• Far in 5 years
• Some pharmacies offer in 
outpatient setting
http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139
PDAPS.org – Naloxone Overdose Prevention Laws
GetNaloxoneNow.org  -- Information on obtaining Naloxone and Training 
Improvised Nasal Spray: 
Prices doubled in 2014 




First patented in 1961 
FDA approved 1971
~$0.20 per dose in 1996
↑ $15 per dose in 2016
Without government funding, 
organizations are having 
trouble providing services to 
growing number in need
2-pack Nasal Spray $139 
Auto-injector list price $4100
For Consumers
Price regulation governed 
by politics and Big Pharma
Average cost:  $10-$3500
Wise move from Surgeon General?
So far…
Italy – Harm reduction service distribution since early 
1990s (doctor supported) – 4-fold reduction since ‘99 
Indications point to yes!
Canadian survey of ER 
doctors found wide support.
Norway, 2014 – Multisite, 
government supported naloxone 
distribution program – Positive 
results 
 Source: United Nations International Narcotics Control Board
Costs pennies per 
dose in many 
countries
$2.40/dose
Only a temporary solution to much larger problem
Problems
Debate of possible “moral hazard” versus addressing root of epidemic
Opioid addiction is systemic problem, requiring years to decades to resolve 
Large amounts of written prescriptions for Naloxone unfilled -- Stigma, cost 
Price issue is not unique to Naloxone
https://www.equities.com/news/naloxone-stocks-who-s-really-winning-the-battle-against-the-opioid-epidemic
Disclosures (fine print)
Naloxone exerts a biphasic effect on amphetamine induced dopamine release, with lower doses 
potentiating (↑) release and higher doses inhibiting (↓) release. 
May be due to the effect of low versus high doses of naloxone on intraterminal calcium influx
Naloxone dose-dependently protects 
against gastric mucosal damage (from 
Indomethacin- and HCl-, but not against 
ethanol-induced)
Pulmonary edema or ventricular fibrillation occasionally has 
occurred shortly after naloxone administration in 
opioid-intoxicated patients. 
Rarely, severe cardiopulmonary effects resulting in death and 
coma have been reported in patients following postoperative 
administration of naloxone. No causal relationship has been 
established.
Both opioid receptor agonists 
and antagonists decrease 
gastric acid secretion. 
Also– It has been found that Naloxone modulates 
endoplasmic reticulum-alpha activity directly and 
indirectly via Mu Opioid Receptors. This suggest that 
naloxone-like compounds may be developed as a novel 
treatment for breast cancer.
• Naloxone is an alkaloid; naturally organic nitrogenous base; Thebaine derivative
• Opioid Antagonist; higher affinity for opioid receptors -- kicks off and takes over
• Deaths from opioid overdose can be prevented by prompt administration of naloxone
• 20 years since take-home naloxone provision was first proposed
• Efforts to improve knowledge of and participation in the take-home naloxone program 
contribute to reducing opioid overdose mortality
• Take-home naloxone kits are not only for patients with current opioid abuse
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